The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
Official Title: A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients With Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma
Study ID: NCT05432375
Brief Summary: The study is designed as an open label, multi-center, Phase 1 study of single agent tinostamustine, used as adjuvant treatment in patients with newly diagnosed GBM who are MGMT unmethylated and have completed concomitant treatment with temozolomide and radiation. Treatment with adjuvant tinostamustine will start within 5 weeks of completion of concomitant temozolomide and radiation. The study is designed to define the MTD by evaluating toxicities during dose escalation. Tinostamustine will be administered on Day 1 of a 21-day treatment cycle. The total number of treatment cycles is 12 for patients who continue to benefit from treatment without disease progression or intolerable toxicity. Patients will enter a "3+3" design with dose escalation/de-escalation depending on safety from the last treated cohort.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona, , Spain
Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, , Spain
South Texas Accelerated Research Therapeutics (START), Madrid, , Spain
Kantonsspital, St Gallen, , Switzerland
University Hospital, Zürich, , Switzerland
Name: Tomas Janik, MD
Affiliation: Mundipharma Research Limited
Role: STUDY_DIRECTOR